Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study - 03/11/23
, Pascale Salameh, PharmD, MPH, PhD, HDR b, c, d, e, f, g, Esra Sarac, MD a, Carolina E. Vera Ayala, MD b, c, Simon Francis Thomsen, MD, PhD h, Torsten Zuberbier, MD, PhD b, c, Luis Felipe Ensina, MD i, Todor A. Popov, MD, PhD j, Martijn B.A. van Doorn, MD, PhD k, l, Ana Maria Giménez-Arnau, MD, PhD m, Riccardo Asero, MD n, Paulo Ricardo Criado, MD, MSc, PhD o, Fernando M. Aarestrup, MD, PhD p, Zainab AbdulHameed Ansari, MD, MRCP q, Salma Al Abri, MD q, Mona Al-Ahmad, MD, FRCPC r, Bushra Al Hinai, SSN q, Anastasiia Allenova, MD, PhD s, t, Maryam Al-Nesf, MD, MScR, ABHS u, Sabine Altrichter, MD b, c, v, Rand Arnaout, MD w, Joanna Bartosińska, MD, PhD x, Andrea Bauer, MD, MPH y, Jonathan A. Bernstein, MD z, Mojca Bizjak, MD, PhD aa, Hanna Bonnekoh, MD b, c, Laurence Bouillet, MD, PhD bb, Zenon Brzoza, MD, PhD cc, Ana Caroline Calvalcanti Dela Bianca Melo, MD, PhD dd, Fernanda L. Campinhos, MD ee, Emily Carne, MD ff, Saleema Cherichi Purayil, MD, ABHS u, Ivan Cherrez-Ojeda, MD, MsC gg, hh, Herberto Jose Chong-Neto, MD, PhD ii, George Christoff, MD, PhD, MPH jj, Niall Conlon, PhD, FRCPath kk, Roberta Fachini Jardim Criado, MD, PhD o, Klara Cvenkel, MD ll, Ebru Damadoglu, MD mm, Inna Danilycheva, MD nn, Cascia Day, MD oo, Laurence de Montjoye, MD, PhD pp, Semra Demir, MD qq, Silvia Mariel Ferucci, MD rr, Daria Fomina, MD, PhD ss, tt, uu, Atsushi Fukunaga, MD, PhD vv, Elizabeth Garcia, MD ww, Asli Gelincik, MD qq, Joe Hannah Göbel, PhD b, c, Kiran Godse, MD, PhD, FRCP xx, Margarida Gonçalo, MD, PhD yy, Maia Gotua, MD, PhD zz, Clive Grattan, MD aaa, Agata Gugala, MD bbb, Carole Guillet, MD ccc, Ali Fuat Kalyoncu, MD mm, Gul Karakaya, MD mm, Alicja Kasperska-Zając, MD, PhD ddd, Constance H. Katelaris, MD, PhD eee, Maryam Khoshkhui, MD fff, Andreas Kleinheinz, MD ggg, Marta Kolacinska-Flont, MD, PhD hhh, Pavel Kolkhir, MD b, c, Mitja Košnik, MD, PhD aa, Dorota Krasowska, MD, PhD x, Muthu Sendhil Kumaran, MD iii, Izabela Kuprys-Lipinska, MD, PhD hhh, Marcin Kurowski, MD, PhD bbb, Elizaveta V. Kuznetsova, MD tt, Désirée Larenas-Linnemann, MD jjj, Marina S. Lebedkina, MD ss, Youngsoo Lee, MD, PhD kkk, Michael Makris, MD, PhD lll, René Maximiliano Gómez, MD mmm, Iman Nasr, MD, MRCP, FRCP, FAAAI q, Sophia Neisinger, MD b, c, Yoshiko Oda, MD nnn, Rabia Öztaş Kara, MD ooo, Esther Bastos Palitot, MD ppp, qqq, Niki Papapostolou, MD lll, Claudio Alberto Salvador Parisi, MD dddd, David Pesque, MD m, Jonathan Peter, MD, PhD oo, Elena Petkova, MD xxx, Katie Ridge, MD kk, Michael Rudenko, MD, PhD, FAAAAI bbbb, Krzysztof Rutkowski, MD, PhD rrr, Sarbjit S. Saini, MD sss, Andac Salman, MD ttt, uuu, Jorge Sanchez, MD, PhD vvv, Bülent Şekerel, MD www, Sofia A. Serdotetskova, MD ss, Faradiba S. Serpa, PhD ee, Bahar Sevimli Dikicier, MD ooo, Nikitas Sidiropoulos, MD lll, Agnieszka Sikora, MD, PhD ddd, Jennifer Astrup Sørensen, MD h, Angele Soria, MD, PhD yyy, Ozlem Su Kucuk, MD zzz, Sherin Rahim Thalappil, MD, ABHS u, Katarzyna Tomaszewska, MD, PhD aaaa, Gulseren Tuncay, MD mm, Derya Unal, MD qq, Solange Valle, MD, PhD cccc, Esmee van Lindonk, MD k, Christian Vestergaard, MD, PhD, DMSc eeee, Raisa Y. Meshkova, MD hhhh, Aleksandr Vitchuk, MD ffff, Paraskevi Xepapadaki, PhD gggg, Young-Min Ye, MD kkk, Anna Zalewska-Janowska, MD, PhD aaaa, Mateusz Zamlynski, MD, PhD ddd, Marcus Maurer, MD b, c, ⁎ 
Graphical abstract |
Abstract |
Background |
Concern about disease exacerbations and fear of reactions after coronavirus disease 2019 (COVID-19) vaccinations are common in chronic urticaria (CU) patients and may lead to vaccine hesitancy.
Objective |
We assessed the frequency and risk factors of CU exacerbation and adverse reactions in CU patients after COVID-19 vaccination.
Methods |
COVAC-CU is an international multicenter study of Urticaria Centers of Reference and Excellence (UCAREs) that retrospectively evaluated the effects of COVID-19 vaccination in CU patients aged ≥18 years and vaccinated with ≥1 dose of any COVID-19 vaccine. We evaluated CU exacerbations and severe allergic reactions as well as other adverse events associated with COVID-19 vaccinations and their association with various CU parameters.
Results |
Across 2769 COVID-19–vaccinated CU patients, most (90%) received at least 2 COVID-19 vaccine doses, and most patients received CU treatment and had well-controlled disease. The rate of COVID-19 vaccination–induced CU exacerbation was 9%. Of 223 patients with CU exacerbation after the first dose, 53.4% experienced recurrence of CU exacerbation after the second dose. CU exacerbation most often started <48 hours after vaccination (59.2%), lasted for a few weeks or less (70%), and was treated mainly with antihistamines (70.3%). Factors that increased the risk for COVID-19 vaccination–induced CU exacerbation included female sex, disease duration shorter than 24 months, having chronic spontaneous versus inducible urticaria, receipt of adenovirus viral vector vaccine, having nonsteroidal anti-inflammatory drug/aspirin intolerance, and having concerns about getting vaccinated; receiving omalizumab treatment and Latino/Hispanic ethnicity lowered the risk. First-dose vaccine–related adverse effects, most commonly local reactions, fever, fatigue, and muscle pain, were reported by 43.5% of CU patients. Seven patients reported severe allergic reactions.
Conclusions |
COVID-19 vaccination leads to disease exacerbation in only a small number of CU patients and is generally well tolerated.
Le texte complet de cet article est disponible en PDF.Key words : Adverse effects, COVID-19, exacerbation, omalizumab, real life, treatment, urticaria, vaccination, vaccine, worsening
Abbreviations used : AE, aOR, ASST, AVV, CI, CIndU, COVID-19, CsA, CSU, CU, GCS, IVV, mRNA, NSAID, SARS-CoV-2, UCARE
Plan
Vol 152 - N° 5
P. 1095-1106 - novembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
